David M. Stern
Impact in
- Clinical Biochemistry top 0.01%
- Advanced Glycation End Products research
- Neurology top 0.05%
- Neuroinflammation and Neurodegeneration Mechanisms
Papers in
-
- Advanced Glycation End Products research 67
-
- S100 Proteins and Annexins 20
- Co-authors
- Ann Marie Schmidt (50 shared papers)Shi Du Yan (34 shared papers)Shi Fang Yan (17 shared papers)Peter P. Nawroth (30 shared papers)Yan Lü (12 shared papers)Thomas Kislinger (9 shared papers)Angelika Bierhaus (16 shared papers)Akihiko Taguchi (26 shared papers)
- Journals
- Journal of Clinical Investigation (21 papers)Journal of Biological Chemistry (14 papers)American Journal Of Pathology (6 papers)The FASEB Journal (6 papers)Journal of Thoracic and Cardiovascular Surgery (6 papers)
- Partner nations
- United StatesJapanGermany
In The Last Decade
David M. Stern
199 papers receiving 31.8k citations
David M. Stern's Hit Papers
Peers
Comparison fields: 5 of 156
- Clinical Biochemistry 12.2k
- Neurology 3.3k
- Endocrinology, Diabetes and Metabolism 4.3k
- Physiology 6.3k
- Developmental Neuroscience 807
Countries citing papers authored by David M. Stern
This map shows the geographic impact of David M. Stern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Stern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Stern more than expected).
Fields of papers citing papers by David M. Stern
This network shows the impact of papers produced by David M. Stern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Stern. The network helps show where David M. Stern may publish in the future.
Co-authors
The 25 scholars most cited alongside David M. Stern, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 202 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Endothelial cells in physiology and in the pathophysiology of vascular disorders. Hit paper breakdown → | 1998 | 1806 |
| 2 | RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease Hit paper breakdown → | 1996 | 1722 |
| 3 | Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases Hit paper breakdown → | 2000 | 1059 |
| 4 | Understanding RAGE, the receptor for advanced glycation end products Hit paper breakdown → | 2005 | 1045 |
| 5 | The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin Hit paper breakdown → | 1995 | 992 |
| 6 | The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses Hit paper breakdown → | 2001 | 970 |
| 7 | Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts Hit paper breakdown → | 1998 | 933 |
| 8 | The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses Hit paper breakdown → | 2001 | 895 |
| 9 | Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE Hit paper breakdown → | 2001 | 870 |
| 10 | N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression Hit paper breakdown → | 1999 | 763 |
| 11 | Activation of Receptor for Advanced Glycation End Products Hit paper breakdown → | 1999 | 647 |
| 12 | Mitochondrial Aβ: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease Hit paper breakdown → | 2005 | 627 |
| 13 | The biology of the receptor for advanced glycation end products and its ligands Hit paper breakdown → | 2000 | 587 |
| 14 | Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesisin a mouse model Hit paper breakdown → | 2004 | 566 |
| 15 | Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesisin a mouse model Hit paper breakdown → | 2004 | 517 |
| 16 | 2003 | 486 | |
| 17 | 2002 | 481 | |
| 18 | 2002 | 458 | |
| 19 | 2005 | 439 | |
| 20 | 2001 | 437 |
About David M. Stern
David M. Stern is a scholar working on Clinical Biochemistry, Molecular Biology, Physiology, Neurology and Immunology, having authored 202 papers that have together received 32.4k indexed citations. Recurring topics across this work include Advanced Glycation End Products research (67 papers), Alzheimer's disease research and treatments (31 papers), Neuroinflammation and Neurodegeneration Mechanisms (26 papers), Blood Coagulation and Thrombosis Mechanisms (24 papers), S100 Proteins and Annexins (20 papers), Endoplasmic Reticulum Stress and Disease (17 papers), Immune Response and Inflammation (13 papers) and Cancer, Hypoxia, and Metabolism (12 papers). The work is most often cited by research in Clinical Biochemistry (12.2k citations), Neurology (3.3k citations), Endocrinology, Diabetes and Metabolism (4.3k citations), Physiology (6.3k citations) and Developmental Neuroscience (807 citations). David M. Stern has collaborated with scholars based in United States, Japan and Germany. Frequent co-authors include Ann Marie Schmidt, Shi Du Yan, Shi Fang Yan, Peter P. Nawroth, Yan Lü, Thomas Kislinger, Angelika Bierhaus, Akihiko Taguchi, Wu Qu and Jean‐Luc Wautier. Their work appears in journals such as Journal of Clinical Investigation, Journal of Biological Chemistry, American Journal Of Pathology, The FASEB Journal and Journal of Thoracic and Cardiovascular Surgery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.